Olga Panes1, César González1, Patricia Hidalgo1, Juan P Valderas2, Mónica Acevedo3, Susana Contreras4, Ximena Sánchez1, Jaime Pereira1, Attilio Rigotti4, Diego Mezzano5. 1. Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Faculty of Medicine and Odontology, University of Antofagasta, Chile. 3. Department of Cardiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 4. Department of Nutrition and Metabolic Diseases, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 5. Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: dmezzano@med.puc.cl.
Abstract
BACKGROUND AND AIMS: High plasma LDL-cholesterol (LDL-C) and platelet responses have major pathogenic roles in atherothrombosis. Thus, statins and anti-platelet drugs constitute mainstays in cardiovascular prevention/treatment. However, the role of platelet tissue factor-dependent procoagulant activity (TF-PCA) has remained unexplored in hypercholesterolemia. We aimed to study platelet TF-PCA and its relationship with membrane cholesterol in vitro and in 45 hypercholesterolemic patients (HC-patients) (LDL-C >3.37 mmol/L, 130 mg/dL) and 37 control subjects (LDL-C <3.37 mmol/L). The effect of 1-month administration of 80 mg/day atorvastatin (n = 21) and 20 mg/day rosuvastatin (n = 24) was compared. METHODS: Platelet TF-PCA was induced by GPIbα activation with VWF-ristocetin. RESULTS: Cholesterol-enriched platelets in vitro had augmented aggregation/secretion and platelet FXa generation (1.65-fold increase, p = 0.01). HC-patients had 1.5-, 2.3- and 2.5-fold increases in platelet cholesterol, TF protein and activity, respectively; their platelets had neither hyper-aggregation nor endogenous thrombin generation (ETP). Rosuvastatin, but not atorvastatin, normalized platelet cholesterol, TF protein and FXa generation. It also increased slightly the plasma HDL-C levels, which correlated negatively with TF-PCA. CONCLUSIONS: Platelets from HC-patients were not hyper-responsive to low concentrations of classical agonists and had normal PRP-ETP, before and after statin administration. However, washed platelets from HC-patients had increased membrane cholesterol, TF protein and TF-PCA. The platelet TF-dependent PCA was specifically expressed after VWF-induced GPIbα activation. Rosuvastatin, but not atorvastatin treatment, normalized the membrane cholesterol, TF protein and TF-PCA in HC-patients, possibly unveiling a new pleiotropic effect of rosuvastatin. Modulation of platelet TF-PCA may become a novel target to prevent/treat atherothrombosis without increasing bleeding risks.
RCT Entities:
BACKGROUND AND AIMS: High plasma LDL-cholesterol (LDL-C) and platelet responses have major pathogenic roles in atherothrombosis. Thus, statins and anti-platelet drugs constitute mainstays in cardiovascular prevention/treatment. However, the role of platelet tissue factor-dependent procoagulant activity (TF-PCA) has remained unexplored in hypercholesterolemia. We aimed to study platelet TF-PCA and its relationship with membrane cholesterol in vitro and in 45 hypercholesterolemicpatients (HC-patients) (LDL-C >3.37 mmol/L, 130 mg/dL) and 37 control subjects (LDL-C <3.37 mmol/L). The effect of 1-month administration of 80 mg/day atorvastatin (n = 21) and 20 mg/day rosuvastatin (n = 24) was compared. METHODS: Platelet TF-PCA was induced by GPIbα activation with VWF-ristocetin. RESULTS:Cholesterol-enriched platelets in vitro had augmented aggregation/secretion and platelet FXa generation (1.65-fold increase, p = 0.01). HC-patients had 1.5-, 2.3- and 2.5-fold increases in platelet cholesterol, TF protein and activity, respectively; their platelets had neither hyper-aggregation nor endogenous thrombin generation (ETP). Rosuvastatin, but not atorvastatin, normalized platelet cholesterol, TF protein and FXa generation. It also increased slightly the plasma HDL-C levels, which correlated negatively with TF-PCA. CONCLUSIONS: Platelets from HC-patients were not hyper-responsive to low concentrations of classical agonists and had normal PRP-ETP, before and after statin administration. However, washed platelets from HC-patients had increased membrane cholesterol, TF protein and TF-PCA. The platelet TF-dependent PCA was specifically expressed after VWF-induced GPIbα activation. Rosuvastatin, but not atorvastatin treatment, normalized the membrane cholesterol, TF protein and TF-PCA in HC-patients, possibly unveiling a new pleiotropic effect of rosuvastatin. Modulation of platelet TF-PCA may become a novel target to prevent/treat atherothrombosis without increasing bleeding risks.
Authors: Moua Yang; Andaleb Kholmukhamedov; Marie L Schulte; Brian C Cooley; Na'il O Scoggins; Jeremy P Wood; Scott J Cameron; Craig N Morrell; Shawn M Jobe; Roy L Silverstein Journal: Blood Adv Date: 2018-11-13
Authors: Valeria Matus; J Guillermo Valenzuela; Patricia Hidalgo; L María Pozo; Olga Panes; Aniela Wozniak; Diego Mezzano; Jaime Pereira; Claudia G Sáez Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240
Authors: Raul R Rodrigues-Diez; Antonio Tejera-Muñoz; Laura Marquez-Exposito; Sandra Rayego-Mateos; Laura Santos Sanchez; Vanessa Marchant; Lucía Tejedor Santamaria; Adrian M Ramos; Alberto Ortiz; Jesus Egido; Marta Ruiz-Ortega Journal: Br J Pharmacol Date: 2020-07-15 Impact factor: 8.739
Authors: Luca De Toni; Claudia Maria Radu; Iva Sabovic; Andrea Di Nisio; Stefano Dall'Acqua; Diego Guidolin; Salvatore Spampinato; Elena Campello; Paolo Simioni; Carlo Foresta Journal: Int J Mol Sci Date: 2020-01-08 Impact factor: 5.923
Authors: Antonio Nenna; Francesco Nappi; Mario Lusini; Umberto Maria Satriano; Davide Schilirò; Cristiano Spadaccio; Massimo Chello Journal: Biomed Res Int Date: 2021-01-23 Impact factor: 3.411